SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias board investigation into CEO Jensen Huangs admitted affair, alongside unverified allegations linking his partner to Chinese intelligence, is driving attention as shares fall. Traders are split between viewing the controversy as a temporary overreaction and worrying about leadership, disclosure, and national-security risks, including speculation about Huangs future as CEO.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims is drawing attention ahead of its Q3 report, with traders debating whether the sharp selloff signals weak results or reflects unexplained price pressure; claims of an earnings leak remain speculation. The Lilly obesity-drug agreement adds to the debate over growth potential versus pressure on margins.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps surge in a low-volume move that traders describe as a possible short squeeze, despite reports of weak or absent fund inflows. Bulls are chasing the momentum, while skeptics question the moves durability and point to possible hopes for easing inflation or Iran tensions as speculative explanations.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp rebound is drawing attention after an Oppenheimer upgrade and Google Clouds use of AMD EPYC processors in its new AI infrastructure; traders also see Nvidia CEO-related headlines prompting a possible rotation into AMD. Bulls point to AI data-center momentum, while skeptics question the valuation and whether the rally can hold.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

A sharp, high-volume rebound ahead of Trade Desks Q3 results is driving attention, with traders speculating about short covering and some unverified earnings-leak rumors. The move is contested: bulls hope for a turnaround, while bears point to weakening ad-growth expectations and worry the report or forward guidance could reverse the rally.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and raised full-year outlook, driven by BRIUMVI growth, dominate discussion; many traders are frustrated that the shares pulled back despite the results, while others are buying the dip. The next major focus is Phase 3 data for a subcutaneous BRIUMVI formulation, with some debate over whether commercial momentum or that readout will matter more.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.11892236 USD and is down -3.62 over the last 24 hours. It is currently trading on 1894 active market(s) with $1,884,610,999.15 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff and heavy liquidations have pressured XRP, with traders also citing political and regulatory uncertainty around crypto policy. The discussion is split between bearish frustration over XRPs continued weakness and holders treating the decline as a buying opportunity.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons quarterly miss and reduced full-year outlook, linked in the discussion to delayed federal Dedrone deployments, have driven a sharp selloff. Traders are split between viewing the drop as a buying opportunity and warning that high valuation and broken price support could mean further downside.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Agility Robotics is drawing attention after a sharp selloff following its de-SPAC debut, with traders blaming post-merger selling and raising concerns about dilution and the companys limited revenue and heavy losses. Others see long-term potential in humanoid robotics and point to commercial orders and strategic backers, leaving the discussion split between SPAC skepticism and confidence in the growth story.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCIs persistent underperformance despite strong reported results and raised guidance is fueling debate over its valuation and whether growth can translate into durable margins and cash flow. Traders also worry that the companys existing accounting and China-related scrutiny could amplify spillover from recent Nvidia allegations, though claims tying SMCI directly to that story remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Edgewise Therapeutics to Participate in Upcoming Investor Conferences Edgewise Therapeutics to Participate in Upcoming Investor ConferencesPR NewswireBOULDER, Colo., Nov. 9, 2026 BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage...

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3...

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results Edgewise Therapeutics Reports Third Quarter 2026 Financial ResultsPR NewswireBOULDER, Colo., Nov. 4, 2026 Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain Phase 3 trial for...

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Nov. 2, 2026 BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400PR NewswireBOULDER, Colo., Oct. 8, 2026 Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at...

Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?

Bristol Myers' Camzyos gains a broader FDA label and strong sales growth, while emerging competitors and pipeline setbacks shape its cardiovascular outlook.

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing RulesPR NewswireBOULDER, Colo., Oct. 1, 2026BOULDER, Colo., Oct. 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc...

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500 Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500PR NewswireBOULDER, Colo., Sept. 22, 2026 - TheMoA that...

Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? 

Bristol Myers??? Camzyos delivers durable five-year benefits, rising sales and potential adolescent label expansion.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

EWTX Stock Hits Record High – Why Servier Is Shelling Out $2.65B For Edgewise’s Muscular Dystrophy Business

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten.</li><li>Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy and a Phase 2 study for Duchenne muscular dystrophy.</li><li>The transaction is expected to close in the third quarter of 2026.</li></ul>Shares of Edgewise Therapeutics (EWTX) soared more than 20% on Monday, climbing to record high, after French drugmaker Servier unveiled a multibillion-dollar deal to acquire the company’s muscular dystrophy business.<a href="https://stocktwits.com/symbol/EWTX">EWTX shares</a> could clock their biggest single-day gains in more than six months if the stock closes at current levels.<h2 class="st-heading-2">EWTX To Receive $1.55B Upfront</h2>On Monday, Servier expanded its footprint in rare neuromuscular disorders through a $2.65 billion deal to acquire Edgewise Therapeutics’ muscular dystrophy business, including programs targeting Becker and Duchenne muscular dystrophies.Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones. The transaction is expected to close in the third quarter of 2026.<h2 class="st-heading-2">EWTX’s Sevasemten In Spotlight</h2>The acquisition includes Edgewise’s muscular dystrophy operations and its lead drug candidate, Sevasemten. The investigational oral therapy is designed to protect fragile muscles from contraction-related damage in patients with rare muscular dystrophies.Sevasemten is currently being evaluated in a pivotal trial for Becker muscular dystrophy (BMD) and a Phase 2 study for Duchenne muscular dystrophy (DMD). There are currently no approved treatments for BMD, a rare genetic disorder that causes progressive muscle weakness and loss of function.“This transaction is designed to place the program in the hands of an organization with the experience and infrastructure to support its continued development for people living with Becker and Duchenne muscular dystrophies,” said Kevin Koch, CEO of Edgewise Therapeutics.<h2 class="st-heading-2">Sevasemten Shows Strong Safety Profile</h2>Edgewise’s MESA extension study is currently evaluating the long-term safety and effectiveness of Sevasemten in patients with Becker muscular dystrophy.According to data presented at the 2026 MDA Clinical and Scientific Conference in March, patients maintained stable physical function for up to 3.5 years, compared with the decline typically seen in the disease. The drug also demonstrated a favorable cardiac safety profile over 12 months, with signs of improved cardiac function in some patients.<h2 class="st-heading-2">EWTX Sentiment Remains Bullish</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.One user noted that upon completion of the deal, Edgewise will become a cardiovascular-focused company.<stembedurl>https://stocktwits.com/G101SPM/message/654951591</stembedurl>The stock has gained around 30% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-glsi-stock-rising-today-form-10k-delay-update-breast-cancer-trial/cZ0gpnyReH0">GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and commercial milestones.

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits Polls

Leak news on M&A on Rythm ,  and one of my favorites $EWTX .. all over Betaville and WSJ ..
When is $VKTX BL   going to step up & do the same ?  …. He talks about high awareness across the industry ?

Biolover

$EWTX 🏥 

Edgewise Therapeutics received favorable FDA End-of-Phase 2 feedback for EDG-7500 in hypertrophic cardiomyopathy and submitted its STRATUS-HCM Phase 3 protocol.

Rayvio | Market News Filter

Raymond James⬆️ $EWTX's PT to $85 from $66 and reiterated Strong Buy after Edgewise Therapeutics announced EOP2 FDA feedback for EDG-7500 in HCM and Ph3 protocol for STRATUS-HCM. 
[CYTK BMY TECX AZN MLYS NVO BAYRY TENX] 
Here's what Raymond James said: The Ph3 protocol largely aligns with our bullish preview (see note here) highlighted by a dose titration schedule that is decoupled from monitoring echocardiograms. 
 
We believe STRATUS is well-positioned to succeed in both the OHCM and nHCM settings and, if positive, can mark a significant advance in the HCM field by bringing a novel mechanism option to patients. 
 
The lack of echo-driven titration strongly suggests that EDG-7500 can potentially avoid cumbersome REMS requirements that have limited uptake and prescriber breadth thus far in oHCM.

Feed

News

Sentiment

Earnings

Fundamentals

Info

EWTX Edgewise Therapeutics Inc

Fundamentals

Latest EWTX News